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Abstract
Cyanovirin-N (CVN) potently inhibits human immunodeficiency virus type 1 (HIV-1) infection, but both cytotoxicity and
immunogenicity have hindered the translation of this protein into a viable therapeutic. A molecular docking analysis
suggested that up to 12 residues were involved in the interaction of the reverse parallel CVN dimer with the oligosaccharide
targets, among which Leu-1 was the most prominent hot spot residue. This finding provided a possible explanation for the
lack of anti-HIV-1 activity observed with N-terminal PEGylated CVN. Therefore, linker-CVN (LCVN) was designed as a CVN
derivative with a flexible and hydrophilic linker (Gly4Ser)3 at the N-terminus. The N-terminal a-amine of LCVN was PEGylated
to create 10 K PEG-aldehyde (ALD)-LCVN. LCVN and 10 K PEG-ALD-LCVN retained the specificity and affinity of CVN for high
mannose N-glycans. Moreover, LCVN exhibited significant anti-HIV-1 activity with attenuated cytotoxicity in the HaCaT
keratinocyte cell line and MT-4 T lymphocyte cell lines. 10 K PEG-ALD-LCVN also efficiently inactivated HIV-1 with
remarkably decreased cytotoxicity and pronounced cell-to-cell fusion inhibitory activity in vitro. The linker-extended CVN
and the mono-PEGylated derivative were determined to be promising candidates for the development of an anti-HIV-1
agent. This derivatization approach provided a model for the PEGylation of biologic candidates without introducing point
mutations.
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Introduction
Currently, over 30 million people worldwide are infected with
human immunodeficiency virus type 1 (HIV-1) and 1.5 million-1.9
million people died from AIDS-related causes at the end of 2011;
approximately 2.2 million-2.8 million people become infected
each year, of whom 95% live in low- and middle-income countries
[1,2]. Microbicides are promising alternative agents for the
prevention of HIV-1 transmission [3]. Cyanovirin-N (CVN), a
protein originally isolated from the freshwater cyanobacterium
Nostoc ellipsosporum, exhibits specific and potent anti-HIV activity by
binding with high affinity to the glycans present on gp120 and
gp41 [4,5]. CVN irreversibly inactivates both laboratory-adapted
and wild type HIV-1 strains during the viral entry stage. The
antiviral effects of CVN also include the inhibition of cell-to-cell
fusion, virus-to-cell fusion and cell-to-cell transmission [6]. CVN
has generated interest as a promising new generation of
microbicides characterized by specific and potent activity, a novel
mechanism of action and unusual physicochemical stability.
CVN may be useful in two different clinical applications, either
as a targeting agent or as a topical microbicide, to prevent the
sexual transmission of HIV-1 by providing a method for female
control over the HIV/AIDS epidemic [7]. Because of its
cyanobacterial origins, CVN exhibits the limitations that are
typical of such proteins in pharmaceutical applications, including a
short plasma half-life, proteolysis and immunogenicity. Polyethyl-
ene glycol (PEG) is a well-studied polymer that is utilized as a
covalent modification on biological macromolecules to improve
biological compatibility by attenuating both immunogenicity and
toxicity, to increase the half-life and to alter the biodistribution [8].
Although the literature has mainly focused on site-selective
PEGylation that generates a single isomer, thereby increasing the
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homogeneity and facilitating the preservation of bioactivity, site-
specific PEGylation at the N-terminus or on random amines on
the side chains of CVN has resulted in inactive molecules [7,9].
The only PEGylated version of CVN that is bioactive is the
mutant Q62C, in which glutamine 62 was replaced with a
cysteine, and the extra free sulfhydryl was site-specifically
PEGylated with maleimide-activated PEG [7]. The in vitro anti-
HIV-1 activity of the Q62C mutant was approximately 50% that
of wild type (WT) CVN. The 20 kDa PEG-CVN Q62C conjugate
demonstrated approximately 80% of the activity observed with
CVN WT. The 30 kDa conjugate had nearly no activity. From
these reported data, we hypothesized that N-terminal residues and
certain lysine residues might exist in or near the glycan binding
sites of CVN.
To confirm this hypothesis, molecular docking and experimen-
tal approaches were utilized to investigate the binding selectivity of
CVN to oligosaccharides with various structures. The protein-
ligand complexes of CVN 3GXY with high mannose N-glycans
were also docked and analyzed to further characterize the hot spot
residues in CVN. This structure-function relationship study
suggested that Leu-1 in the N terminus was the most important
hot spot residue for binding to Man729GlcNAc2 glycans.
Therefore, a rational PEGylation process was designed to avoid
blocking the N-terminal hot spot residues.
The well documented (Gly4Ser)3 molecule is a flexible
hydrophilic linker peptide that has been utilized to fuse 2
independent polypeptides into a protein with multiple domains
and functions [10]. Based on the merits of the (Gly4Ser)3 linker
peptide and the conundrum of CVN PEGylation, we extended the
N-terminus of CVN with (Gly4Ser)3 to create linker-CVN (LCVN)
and performed site-specific PEGylation of LCVN at the N-
terminal amine group using mPEG-aldehyde (ALD). We hypoth-
esized that this PEG-linker-CVN might preserve the bioactivity of
CVN by separating the large PEG group from the CVN active site
as well as facilitate the preparation of highly homogenous
PEGylated products. This strategy avoided introducing a point
mutation into the primary sequence of CVN that could alter its
bioactivity.
There is no sequence homology greater than 8 contiguous
amino acids or 20% of the total sequence between CVN and any
other known proteins. The extremely low sequence homology in
addition to the 2 intramolecular disulfide bonds in CVN makes the
artificial production of this protein in Escherichia coli (E. coli) difficult
[6]. In a previous study, biologically functional CVN was
efficiently expressed in the cytoplasm of E. coli after fusion to
small ubiquitin-related modifier (SUMO) coupled with a hexahis-
tidine tag [11]. Utilizing this strategy, the fusion gene his6-sumo-
linker-cvn was constructed to efficiently produce soluble LCVN in
E. coli. The N-terminal PEGylation of LCVN was performed to
create 10 K PEG-ALD-LCVN, a site-specific PEG conjugate of
LCVN. Subsequently, the gp120, gp41 and oligosaccharide
binding characteristics of LCVN and 10 K PEG-ALD-LCVN
were evaluated. The anti-HIV-1 activity and cytotoxicity of these
2 CVN derivatives were determined by MTT and syncytium-
formation assays to elucidate the effects of the linker peptide on
oligosaccharide binding and the anti-HIV-1 activity of CVN and
to explore the feasibility of site-specific PEGylation of pharma-
ceutical proteins via the (Gly4Ser)3 extension.
Results
CVN Targeting to 24 Potential Oligosaccharides that were
Selected from a Pool of 6 Types of N-glycans by
Molecular Docking
Molecular docking was performed to determine the binding
selectivity of CVN for oligosaccharides with various structures and
to clarify the binding modes. The crystallization data for CVN
(Figure S1) (http://www.rcsb.org/pdb) was utilized to dock 53
oligosaccharide targets that were selected to represent 6 types of
carbohydrate structures. These oligosaccharides included 13
complex N-glycans, 13 high mannose N-glycans, 13 branched
and linear oligomannoses, 3 hybrid N-glycans, 3 N-glycans with a
core pentasaccharide or related moiety and 8 oligosaccharides
originating from glycolipids (Figure 1). The consensus scores (CS)
for the 53 oligosaccharides are listed in Table 1. High scores
indicated improved biological activity. Several complex and
hybrid N-glycans exhibited a high CS. Oligosaccharides No. 1,
2, 4, 10 and 42 were characterized with a CS .0.5. Most high
mannose N-glycans (No. 14–26) had a CS between 0.2 and 0.5.
Several oligomannose moieties had a CS of zero.
To characterize the CVN binding potential, dozens of high-
scoring and commercially available oligosaccharides were selected
from each oligosaccharide category for further investigation.
According to this priority principle, 7 oligosaccharides (No. 1–2,
4–6, 9 and 10) that belonged to the maximum CS group were
selected to represent the complex N-glycans. Nine oligosaccharides
(No. 14–17, 19–22 and 24) that belonged to the medium CS group
were selected to represent the high mannose N-glycans. From all
the branched and linear oligomannoses in the minimum CS
group, glycans No. 27–30 and 43 were selected to represent N-
glycans with a pentasaccharide core, and No. 46–47 and 52
represented oligosaccharides originating from glycolipids. In total,
24 oligosaccharides (asterisks, Figure 1) were selected to represent
the diverse carbohydrate structures in the centrifugal ultrafiltra-
tion-HPLC assays.
Specific Recognition of CVN by Non-reduced Terminal
Mana122Man Residues in Man729GlcNAc2 Glycans
To verify the MOE docking data and evaluate the minimum
oligosaccharide structure required for high-affinity binding to
CVN, centrifugal ultrafiltration-HPLC was performed using
fluorescence-labeled oligosaccharides (PA-oligosaccharides). The
structures of the 24 oligosaccharides utilized in this study are
indicated with asterisks in Figure 1. Before testing LCVN binding
to the selected oligosaccharides, the optimum pH for the binding
assay was determined using PA-heptasaccharide (No. 19, Figure 1)
in 50 mM 2-(N-morpholino)ethanesulfonic acid (MES, pH 5.0),
50 mM sodium phosphate (pH 6.0) and 50 mM Tris-HCl
(pH 7.0, 8.0 or 9.0). Similar assays were performed to optimize
the reaction time from 20 to 100 min in 50 mM Tris-HCl
(pH 7.0). Maximal CVN-oligosaccharide binding was achieved at
pH 7.0–9.0 (Figure 2A) after a 60 min incubation period. The
binding of CVN to its targets was stable after incubating for
60 min or longer (Figure 2B). Therefore, the binding of CVN to
the selected PA-oligosaccharides was assayed at room temperature
for 60 min at pH 7.0.
CVN exclusively bound to high mannose N-glycans (No. 15–22)
without recognizing other oligosaccharides, including oligoman-
nose (No. 27–30), complex N-glycans (No. 1–10) and oligosac-
charides with a pentasaccharide core (No. 43) (Figure 2C).
Glycolipid oligosaccharides (No. 46, 47 and 52) did not interact
with CVN. The high mannose N-glycans (No. 16–17 and 19–22)
bound to CVN with a binding ratio greater than 85% (Figure 2C).
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CVN bound with high affinity to Man7GlcNAc2 with 1 non-
reduced terminal Mana1–2Man moiety in the D1 or D3 arm (No.
17 and 19). Man8GlcNAc2 with 2 exposed Mana1–2Man moieties
in the D1, D2 or D3 arms (No. 20–22) or Man9GlcNAc2 with 3
Mana1–2Man moieties (No. 16) exhibited a strong interaction with
CVN. The binding ratio decreased to 37% for oligosaccharide No.
15, which only has 1 non-reducing terminal Mana122Man moiety
in the D1 arm provided by Man6GlcNAc2. These data clearly
suggested that CVN exhibited strict specificity for high mannose
N-glycans by recognizing the extended carbohydrate structure of
the non-reducing terminal Mana122Man moieties in the D1, D2
or D3 arms provided by Man729GlcNAc2 (No. 16–17 and 19–22).
Oligosaccharide Mana122Man Binding to the Hot Spot
Residues was Critical for the Oligosaccharide-CVN
Interaction
To characterize the structural interactions between CVN and its
ligands, oligosaccharides No. 22 and 28 were selected to represent
an active and a less active group, respectively, for further analysis.
The active pocket of CVN 3GXY is located in the gap between
the b sheet of chains A and B. The extended structure of the non-
reducing terminal mannose moieties in the oligosaccharide bound
to the active pocket of CVN, whereas the other part of the
oligosaccharide was exposed outside of the pocket (Figure 3). An
overview of the protein-ligand interactions for oligosaccharides
No. 22 and 28 is presented in Figure 3. For oligosaccharide No.
22, hydrogen bonds formed between the ligand and Leu-1, Lys-3,
Thy-7, Glu-23, Thr-25, Tyr-29 and Glu-101 in the active site
Figure 1. The PA-oligosaccharide structures utilized for the molecular docking and experimental target binding assays with LCVNs.
A panel of 53 oligosaccharides was selected to represent the diverse carbohydrate structures. All these oligosaccharides were utilized in the docking
experiments. After the docking simulation, 24 oligosaccharides (indicated by asterisks) were selected for further analysis by the centrifugal
ultrafiltration-HPLC assay.
doi:10.1371/journal.pone.0086455.g001
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(Figure 3A); for oligosaccharide 28, hydrogen bonds were present
between the ligand and Leu-1, Gly-2, Lys-3, Thr-7, Thr-25 and
Asn-93 (Figure 3B). Although both the active and the less active
oligosaccharides interacted with 6 residues in CVN, the binding
energy for oligosaccharide No. 22 was 271.32 kcal/mol, which
was lower than that for oligosaccharide No. 28 (244.16 kcal/mol).
The multiple hydrogen bond interactions and the lower binding
energy for the oligosaccharide No. 22-CVN complex correspond-
ed with the greater activity of this particular oligosaccharide.
Even with the differences in binding energy, oligosaccharides
No. 22 and 28 interacted with the same 4 amino acids, Leu-1, Lys-
3, Thy-7 and Thr-25 (Figure 3). For oligosaccharide No. 22, 5
amino acids (Leu-1, Lys-3, Thr-7, Thr-25 and Glu-101) interacted
with the extended non-reducing terminal mannose moieties. In
contrast, only 1 residue (Thr-25) interacted with the mannose of
oligosaccharide No. 28, indicating that the multiple mannoses
interacting with multiple residues contributed to the robust activity
of oligosaccharide No. 22.
To further characterize the hot spot residues in CVN and its
derivatives, protein-ligand complexes of CVN 3GXY with all 6
high mannose N-glycans (No. 16–17 and 19–22) were docked and
analyzed by MOE. The frequencies at which the hot spot residues
were directly involved in the interactions are presented in
Figure 4A. In total, 12 amino acids (Leu-1, Gly-2, Lys-3, Gln-6,
Thr-7, Tyr-9, Glu-23, Thr-25, Gly-27, Asn-93, Asp-95 and Glu-
101) in CVN were involved in binding to oligosaccharide ligands.
Most of these residues could form hydrogen bonds with the
ligands. All 6 oligosaccharides bound to Leu-1, and over half of the
ligands bound to Gly-2, Lys-3, Gln-6, Glu-23, Asn-93 and Glu-
101. The 3D structure formed by the 12 hot spot residues (the
binding residues) was defined as a new binding pocket in CVN for
oligosaccharides. This binding pocket could be utilized as a
reference for further molecular docking studies to select novel
ligands.
To illustrate the type of mannose structure that was specifically
targeted in the oligosaccharide-CVN (3GXY) binding model and
to evaluate the consistency with the centrifugal ultrafiltration-
HPLC assay, all the binding moieties in the 6 oligosaccharides
were analyzed and summarized as the number of total targeting
residues in CVN and the number of Mana122Man-targeting
Table 1. MOE docking values for 53 oligosaccharides in the training set.
Number Consensus score x y Number Consensus score x y
Complex type 29 0.00 245.26 221.92
1 0.50 274.17 236.92 30 0.01 246.64 222.00
2 0.64 285.65 235.73 31 0.09 255.72 227.16
3 0.40 273.56 233.71 32 0.09 258.58 225.52
4 0.87 284.39 242.26 33 0.07 256.84 224.86
6 0.28 264.58 233.62 34 0.07 258.52 224.73
7 0.31 277.59 229.06 35 0.05 252.76 225.31
8 0.36 284.63 228.71 36 0.02 248.68 223.08
9 0.19 268.80 227.49 37 0.00 244.68 221.35
10 0.69 290.33 235.18 38 0.00 247.01 219.31
11 0.17 267.25 226.93 39 0.02 248.96 223.47
12 0.11 259.78 226.89
13 0.28 274.23 229.28 Hybrid type
High-mannose type 40 0.27 268.94 230.65
14 0.23 263.13 232.25 41 0.25 269.04 229.78
15 0.18 267.32 227.55 42 0.68 279.95 239.30
16 0.25 267.67 230.66 Core and relatives
17 0.27 264.41 233.04 43 0.12 263.93 225.68
18 0.26 269.41 230.21 44 0.09 261.16 225.05
19 0.43 277.20 233.21 45 0.05 257.87 223.34
20 0.29 275.00 229.31 Oligosaccharides from glycolipids
21 0.25 271.72 228.58 46 0.04 254.39 223.50
22 0.35 271.32 232.77 47 0.01 246.37 222.41
24 0.25 269.83 229.67 48 0.00 253.08 219.50
25 0.14 260.42 228.27 49 0.10 262.76 224.86
26 0.05 255.69 224.21 50 0.14 260.98 228.20
Oligomannoses 51 0.04 259.08 221.89
27 0.00 243.73 221.50 52 0.07 257.67 224.55
28 0.00 244.16 225.87 53 0.07 256.60 222.76
x, the docking energy for 3GXY;
y, the docking energy for 2PYS.
doi:10.1371/journal.pone.0086455.t001
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residues involved in binding to each oligosaccharide (Figure 4B).
For CVN, 4–10 residues bound to each oligosaccharide with 2–4
Mana122Man-targeting residues. In general, 63% of the binding
occurred between hot spot residues and Mana122Man moieties.
Oligosaccharide No. 19 was targeted by 10 amino acids, with 3 of
these hot spot residues targeting the extended non-reducing
terminal Mana122Man moieties. These data were consistent with
the centrifugal ultrafiltration-HPLC study, suggesting that CVN
specifically recognized the extended non-reducing terminal
Mana122Man moieties provided by Man7–9GlcNAc2.
Because oligosaccharide No.19 was targeted by most hot spot
residues, the 3D model of CVN 3GXY binding to this
oligosaccharide is illustrated in Figure 4C. The 10 binding
residues were Leu-1, Gly-2, Gln-6, Tyr-9, Glu-23, Thr-25, Gly-
27, Asn-93, Asp-95 and Glu-101 (highlighted in light pink). The
hydrogen bonds are indicated by dashed lines. Three of these hot
Figure 2. Binding specificities of CVN to PA-oligosaccharides. The optimum (A) pH and (B) reaction time for CVN binding to PA-
heptasaccharide (No. 19, Figure 1) were determined via centrifugal ultrafiltration-HPLC, and subsequently the (C) binding activity (specificity) of CVN
and the 24 oligosaccharides was measured. The right panel in (C) depicts the non-reducing terminal Mana122Man moieties in the D1, D2 or D3 arms
of the Man729GlcNAc2 glycans that participated in the binding. Two independent experiments were performed for each PA-oligosaccharide, and the
binding activity is presented as the average of the duplicate assays.
doi:10.1371/journal.pone.0086455.g002
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spot residues, Gln-6, Tyr-9 and Glu-23, targeted the extended
non-reducing terminal Mana122Man moieties. This model
provided insight into the CVN-oligosaccharide interaction.
Both LCVN and the PEGylated Product Retained the
Specificity and Affinity of CVN for Man729GlcNAc2
Glycans
The structure-function relationship study suggested that Leu-1
in the N terminus of CVN was the most important hot spot residue
for binding to Man729GlcNAc2 glycans and that most of the N1 to
Figure 3. The mode of CVN binding to oligosaccharides. An overview of the mode of CVN binding to oligosaccharides (A) No. 22 and (B) No.
28 is presented. The fuzzy blue blob indicates ligand exposure to the solvent. For oligosaccharide 22, which exhibited strong binding, Leu-1, Lys-3,
Thy-7, Glu-23, Thr-25, Tyr-29 and Glu-101 were involved in the protein-ligand interaction. For oligosaccharide No. 28, which was characterized by
weak binding, the docking simulation indicated that hydrogen bonds formed between the ligand and Leu-1, Gly-2, Lys-3, Thr-7, Thr-25 and Asn-93.
doi:10.1371/journal.pone.0086455.g003
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N7 residues in the N terminus were involved in the binding.
Therefore, LCVN, a CVN derivative with a (Gly4Ser)3 oligopep-
tide extension at the N terminus, was constructed to retain the
integrity of the binding sites in CVN. The N-terminal a-amine of
LCVN was PEGylated to create 10 K PEG-ALD-LCVN
(Figure 5).
The gp120 and gp41 binding activities of LCVN and 10 K
PEG-ALD-LCVN were determined to characterize their glycan
binding ability. As a positive control, CVN bound to glycosylated
gp41 (Figure 6A) and gp120 (Figure 6B) in a dose-dependent
manner but did not exhibit any affinity for non-glycosylated gp41
(Figure 6C) or gp120 (Figure 6D). CVN bound more tightly to
gp41 than to gp120. LCVN and 10 K PEG-ALD-LCVN had the
same binding specificity to the glycosylated substrates (Figure 6A-
6D), but their affinities were slightly decreased compared with
CVN. These data suggested that both LCVN and 10 K PEG-
ALD-LCVN maintained the glycan-specific binding of native
CVN to both gp120 and gp41.
The binding of LCVN and 10 K PEG-ALD-LCVN to the 24
oligosaccharides (asterisks, Figure 1) selected to represent diverse
carbohydrate structures was determined to characterize the glycan
specificity. The centrifugal ultrafiltration-HPLC assays indicated
that the 2 proteins exclusively recognized high mannose N-glycans
(No. 15–22) over other types of oligosaccharides (No. 1–10, 27–30,
43, 46, 47 and 52) (Figure 6E). Although LCVN exhibited a
slightly decreased affinity to high mannose N-glycans No. 19 and
21, it bound to high mannose N-glycans No. 16, 17, 20 and 22
with binding ratios of 100%. The binding ratio for oligosaccharide
No. 15, which has 1 non-reducing terminal Mana122Man moiety
in Man6GlcNAc2, and LCVN decreased to ,40%, which
corresponds with the data for CVN (Figures 6E and 2C). These
data clearly suggested that both LCVN and 10 K PEG-ALD-
LCVN retained the affinity of CVN for specific oligosaccharides.
All 3 versions of CVN had identical target specificity and
consistent binding potency to the extended carbohydrate structure
of the non-reducing terminal Mana122Man moieties in the D1,
D2 or D3 arms provided by Man729GlcNAc2 glycans.
LCVN Cytotoxicity was Significantly Lower and was
Further Attenuated by PEGylation
As promising microbicide candidates, CVN and its derivatives
would be applied topically on human skin and/or mucosa. The
HaCaT keratinocyte cell line and the MT-4 T lymphocyte cell line
were utilized to evaluate the in vitro cytotoxicity of LCVN and its
derivatives. Both LCVN and 10 K PEG-ALD-LCVN exhibited
significantly less cytotoxicity than native CVN (Table 2). For
HaCaT cells treated for 24 h, the CC50 values for LCVN and
10 K PEG-ALD-LCVN were 8.5961.31 mM and .12.00 mM,
respectively. The value for native CVN was 1.7460.22 mM,
suggesting that the cytotoxicity of LCVN was approximately 1/6
that of CVN. For 10 K PEG-ALD-LCVN, the cytotoxicity was
,1/10 that of CVN. After treating the cells for 48 h, LCVN
exhibited less cytotoxicity than CVN, and 10 K PEG-ALD-LCVN
was approximately 1/6 as cytotoxic as native CVN. The MT-4 T
lymphocyte cell line was sensitive to the various versions of CVN,
with both LCVN and the PEGylated product exhibiting signifi-
cantly reduced toxicity (Table 3). The cytotoxicity of LCVN was
approximately 1/4 that for CVN. For 10 K PEG-ALD-LCVN,
the ratio was 1/42. These data suggested that LCVN was
remarkably less cytotoxic than native CVN and that the in vitro
toxicity was further reduced by PEGylation. The addition of the
15-aa extension (linker) at the N-terminus of CVN decreased the
cytotoxicity. After PEGylation, this toxicity decreased by approx-
imately 40-fold. These results suggested that further examination
of these modified proteins for potential anti-HIV activity would be
beneficial.
LCVN Exhibited More Potent Anti-HIV-1 Activity in the
Nanomolar Range
The anti-HIV activities of both LCVN and 10 K PEG-ALD-
LCVN were determined by the WST-1 method. As presented in
Table 3, LCVN and the PEGylated product protected MT-4 cells
from infection with HIV-1/IIIB. The IC50 of LCVN was
14.3661.35 nM and that for native CVN was 21.8362.79 nM,
suggesting that LCVN possessed more anti-HIV activity than
native CVN. Although 10 K PEG-ALD-LCVN exhibited signif-
icantly less anti-HIV activity than both LCVN and CVN, the
cytotoxicity to MT-4 cells was also significantly decreased.
Considering activity and cytotoxicity, both LCVN and 10 K
PEG-ALD-LCVN exhibited improved safety profiles. The SI
values for LCVN and 10 K PEG-ALD-LCVN were approxi-
mately 5-fold higher than that for CVN. Among the 3 CVN
derivatives, LCVN exhibited the most potent anti-HIV activity,
the highest SI value and the lowest cytotoxicity. The derivative
10 K PEG-ALD-LCVN retained the potent anti-HIV activity of
CVN in the nanomolar range and possessed the lowest cytotox-
icity, which was similar to that of AZT.
Figure 4. Characterization of CVN binding to high mannose oligosaccharides. (A) The frequencies of the hot spot residues that target the 6
high mannose oligosaccharides were calculated. Leu-1 represents the N-terminal leucine in the B chain, which was involved in oligosaccharide
binding with a frequency of 100%. (B) The total number of targeting residues (black column) and Mana122Man binding residues (grey column) for
CVN binding to the 6 oligosaccharides is presented. (C) The 3D model of CVN 3GXY binding to oligosaccharide No. 19 is illustrated. The 10 residues in
CVN that were involved in the binding are colored in light pink, and their ligands are depicted in green. The hydrogen bonds are illustrated as dashed
light pink lines.
doi:10.1371/journal.pone.0086455.g004
Figure 5. Structural schematics of LCVN and the PEGylated product. The N-terminal glycine of LCVN and the serine-leucine joint between
the linker and the CVN sequence are indicated. The blank rectangle represents the residual polypeptide of CVN. 10 KD mPEG-ALD was selectively
reacted with the N-terminal a-amine of LCVN at different pKa values to create 10 K PEG-ALD-LCVN.
doi:10.1371/journal.pone.0086455.g005
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Figure 6. The binding of LCVNs to HIV-1 envelope proteins and oligosaccharides. The binding of LCVNs to glycosylated (A) gp41 and (B)
gp120 and non-glycosylated (C) gp41 and (D) gp120 was determined by ELISA. CVN served as the positive control, and BSA was utilized as the
negative control. The data points represent the mean6SD of independent triplicate experiments. (E) The LCVN binding activity (specificity) with the
The PEGylation and Activity of Linker-Extended CVN
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LCVN Exhibited Significantly Greater Fusion Inhibitory
Activity than CVN
HIV-1 spreads efficiently, primarily via cell-to-cell fusion. To
determine the fusion inhibitory activity of LCVN and its
PEGylated conjugate, a cell-to-cell fusion assay was performed
according to the method of Tochikura et al. [12]. In this syncytium
formation assay, MOLT-4 cells were co-cultured with HIV-
producing MOLT-4/IIIB cells for 24 h in the presence of LCVN
or its derivatives. The results demonstrated that the fusion
inhibitory activity of LCVN was significantly greater than that
of CVN; PEGylation further enhanced this activity in the high and
medium dose groups (Figure 7). In the lower dose group (28 nM),
10 K PEG-ALD-LCVN exhibited less inhibitory activity than
LCVN, but its activity remained higher than that of CVN. These
data confirmed the merits of enhancing bioactivity and attenuating
toxicity by adding an N-terminal linker (LCVN) and suggested
that the PEG groups in 10 K PEG-ALD-LCVN might interfere
with the fusion of HIV-1-positive cells to normal ones by steric
hindrance. This hypothesis and these data provided insight into
the mechanism of HIV-1 transmission and will aid the discovery
and development of novel fusion inhibitory compounds.
Discussion
A microbicide must not damage the mucosa because such
damage may increase the risk of HIV-1 infection. Significant
efforts had been made to reduce the toxicity and increase the anti-
HIV activity of microbicide candidates, such as CVN. In this
study, the structure-function relationship for CVN was investigat-
ed to identify a more rational structure for a CVN derivative for
further optimization. After the first docking of CVN 3GXY and
2PYS to the 53 oligosaccharides, most complex and hybrid N-
glycans exhibited a high CS with low or no binding in the
experimental assays. By analyzing the protein-ligand binding
modes, the nitrogen in the oligosaccharide was determined to
interact with the amino acids of CVN, accounting for the majority
of the binding free energy. CVN did not interact with
oligomannose (No. 27) and had a low affinity for Man6GlcNAc2
glycan (No. 15). These data suggested that the Man5GlcNAc2 core
in N-glycans with 6–9 mannose moieties was essential for the
interaction with CVN and its mutants. The terminal Mana122-
Man moieties and the conformation of the glycosidic linkage
between the terminal disaccharide and the core residue(s) structure
might be responsible for the observed selectivity.
Multiple experimental and computational methods, including
crystallization, molecular dynamics (MD) simulations and point
mutation studies, have been utilized to investigate the antiviral
mechanisms of action and to optimize the structural features of
CVN [13,14,15,16,17,18]. In our experimental assays, CVN,
LCVN and the PEGylated conjugate exclusively bound to high
mannose N-glycans (No. 16–17 and 19–22) without recognizing
other N-glycans. This was consistent with the docking analyses
that suggested that 63% of the binding residues were formed by
the Mana122Man moiety. Our data and a previous STD-NMR
study suggested that both the terminal disaccharide and the
reducing mannose residue influenced the affinity and the
selectivity of interactions with CVN [19]. Furthermore, we
discovered that CVN recognized Man8GlcNAc2 and Man9-
GlcNAc2 glycans with 2 or 3 reducing Mana122Man ends [17]
and Man7GlcNAc2 glycans with 1 reducing end. In contrast with
STD-NMR studies that utilized the di- and tri-mannoside
substructures of Man-9 to determine the oligosaccharide specificity
of CVN, we selected 5 different types of Man7–9GlcNAc2 glycans
that represented the carbohydrate structures of gp120 [20]. These
data could be utilized to determine the type of carbohydrate
structures in gp120 that could be targeted by CVN and LCVNs
with high affinity.
Thirteen residues, Gly-2, Lys-3, Thr-7, Glu-23, Asn-42, Asp-44,
Ser-52, Asn-53, Thr-57, Lys-74, Gln-78, Asn-93 and Asp-95
(Table S1), interacted with the oligomannose ligands in the crystal
data for CVN 3GXY, 3GXZ, 2PYS, 1IIY and 2RDK. As
illustrated in Figure 4, molecular docking suggested that 12
residues were involved in the binding of CVN 3GXY/Z to the 6
high mannose N-glycans. Among these hot spot residues, Gly-2,
Lys-3, Thr-7, Glu-23, Asn-93 and Asp-95 were identified in the
crystal structures and the simulated oligosaccharide-CVN 3GXY/
Z complexes.
The binding of the 6 N-glycans to the 3 parallel CVN dimers
2PYS, 1IIY and 2RDK was analyzed. The docking analysis
suggested that 8 residues were hot spots: Glu-41, Asn-42, Ser-52,
Asn-53, Glu-56, Thr-57, Lys-74 and Arg-76. Five residues, Asn-
42, Ser-52, Asn-53, Thr-57 and Lys-74, were present in both the
crystallography and the computational data. Among the residues
from the docking data, Glu-41 was the most important hot spot
residue, with a frequency of 83%, suggesting that Glu-41 might be
one of the critical binding residues in the parallel CVN dimer;
however, this residue was not present in the crystallographic
protein-oligomannose complex. Among all the hot spot residues
involved in binding, 55% of them bound to the Mana122Man
moiety of the oligosaccharide (data not shown).
24 oligosaccharides was assayed by centrifugal ultrafiltration-HPLC. Two independent experiments were performed for each PA-oligosaccharide, and
the binding activity is presented as the average of the duplicate assays.
doi:10.1371/journal.pone.0086455.g006
Table 2. The cytotoxicity of LCVN and its PEGylated
derivatives in HaCaT cells (mean6SD, n = 3).
Cytotoxicity (CC50, mM)
24 h 48 h
LCVN 8.5961.31 1.7560.14
10 K PEG-ALD-LCVN .12.00 6.1160.29
CVN 1.7460.22 1.1860.09
CC50, 50% cell inhibitory concentration.
doi:10.1371/journal.pone.0086455.t002
Table 3. The anti-HIV-1 activity and MT-4 cytotoxicity of
LCVNs (mean6SD, n = 3).
IC50 (nM) CC50 (nM) SI
LCVN 14.3661.35 647.15693.42 45.06
10 K PEG-ALD-LCVN 176.40625.03 7181.076861.72 40.71
CVN 21.8362.79 169.56613.63 7.77
AZT 36.5565.64 .4482 .122.63
IC50, 50% viral inhibitory concentration;
CC50, 50% cell inhibitory concentration;
SI, the ratio of CC50 to IC50.
doi:10.1371/journal.pone.0086455.t003
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Figure 7. LCVN fusion inhibitory activity. (A) Phase-contrast micrographs were obtained 24 h after co-culturing normal MOLT-4 and HIV-1-
positive cells in the presence of LCVN. The HIV-1-induced multinucleated giant cells are indicated by black arrows. (B) The relative fusion inhibition
rates (%) for LCVN and its derivatives were calculated (**P,0.01 vs. CVN, * P,0.05 vs. CVN).
doi:10.1371/journal.pone.0086455.g007
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A comparison of the docking and the crystallography data for
the 2 types of CVN dimers with the experimental glycan/
oligosaccharide binding assay data suggested that (i) the simula-
tions of the CVN-oligosaccharide complexes were highly consis-
tent with the interaction mode suggested by crystallography and
(ii) the simulation had high fidelity with the experimental assay. An
analysis of the docking of CVN to the oligosaccharides suggested
that (i) Leu-1, Gly-2, Lys-3, Thr-7, Glu-23, Asn-93 and Asp-95
were particularly important for the binding of reverse parallel
CVN to its targets, with Leu-1 being the most predominant hot
spot residue; and (ii) in parallel CVN dimers, Glu-41, Asn-42, Asn-
53, Thr-57 and Lys-74 were the most important hot spot residues.
This binding model provided a possible explanation for the
reduction in bioactivity for N-terminal PEGylated CVN and also
supported our strategy of utilizing PEGylation in conjunction with
a linker to separate the large PEG group from the oligosaccharide
binding site in CVN. Furthermore, it was deduced that CVN
might be more inclined to form a reverse parallel structure in
solution because N-terminal PEGylated CVN was reported to be
fully inactive, but all the hot spot residues are located in the center
of parallel CVN [7].
Gp120 is responsible for target cell tropism and viral attachment
via an interaction with the cell surface receptor CD4 and the co-
receptors CCR5 or CXCR4 [21,22]. The binding of gp120 to its
receptor and co-receptor induces a cascade of refolding events in
gp41 that bring the viral and cell membranes together [23]. CVN
binds with high affinity to glycosylated gp120 and gp41. The
stronger binding to gp41 than gp120 suggested that CVN
interferes with the process of HIV receptor recognition and
membrane fusion. In addition, CVN may act at the stage of
membrane fusion by binding to gp41, thereby inhibiting the gp41
refolding events.
Based on the knowledge above, LCVN was designed and
further modified at the N-terminus using a site-specific method
and 10 KD mPEG-ALD to maintain the integrity of the binding
sites in CVN. LCVN exhibited greater anti-HIV-1/IIIB activity in
the MTT and fusion inhibitory assays and lower cytotoxicity than
native CVN. The enhanced bioactivity of LCVNs may have
resulted from (i) the (Gly4Ser)3 linker contributing to correct
folding and the proper biological function of the linker-tagged
protein [24]; (ii) the increased molecular weight and the enhanced
thermostability that amplified the steric hindrance of LCVN,
increasing the fusion inhibitory activity [25]; and (iii) the
hydrophilicity of the flexible linker, which could interfere with
the structural integrity of the viral envelope. It would be interesting
to fully elucidate the mechanism by which LCVN exhibited
enhanced anti-HIV-1 activity.
The anti-HIV-1/IIIB activity of 10 KD mPEG-ALD was
significantly decreased in the WST-1 assay, but this LCVN
derivative exhibited more potent fusion inhibitory activity than
native CVN. WST-1 is a substrate that measures the metabolic
activity of viable cells, so the WST-1 assay indirectly evaluates the
anti-viral activity of a tested compound. The fusion inhibitory
assay directly measures the antiviral activity of CVN because this
assay simulates the actual process of HIV-1 transmission between
normal and HIV-1-infected cells. Therefore, the fusion inhibitory
assay is more pertinent for studying the antiviral mechanism of
action of CVN. The fusion inhibitory activity of 10 K PEG-ALD-
LCVN was greater than that of LCVN. These data strengthened
the therapeutic potential for 10 K PEG-ALD-LCVN and
suggested that the molecular weight of CVN and its derivatives
might be crucial for antiviral activity. The steric hindrance effect
might be involved in the antiviral mechanism of action of 10 K
PEG-ALD-LCVN. Other groups have reported that derivatives
with a higher molecular weight, such as the engineered CVN
dimer, have greater antiviral activity than monomeric forms of
CVN [26]. An interesting recent report demonstrated that fusions
of CVN and the gp41 membrane-proximal external region
(MPER) peptide joined by a (Gly4Ser)x linker (where x is 4 or 8)
induce specific, irreversible lysis of pseudotyped HIV-1 virions and
fully infectious HIV-1 virions [27]. Both fusion components, CVN
and MPER, are required for the cell-free virolysis of HIV-1.
Considering the merits of the PEG-linker-CVN that we demon-
strated here, it would be interesting to create a chimeric CVN
derivative with N-terminal PEGylation and a C-terminal MPER
fusion and to explore the potential of this novel agent, PEG-linker-
CVN-linker-MPER, as a tri-acting virucidal entry inhibitor of HIV-
1.
It would be prudent to test the anti-HIV-1 activity of LCVN
and its PEGylated conjugate on additional HIV-1 strains. Here,
we only utilized HIV-1/IIIB as a model strain to evaluate the
potential of LCVN and the PEG-LCVN conjugate. It has been
well validated that CVN irreversibly inactivates a broad range of
laboratory-adapted HIV strains and clinical isolates with different
tropisms at the nanomolar level [28,30]. For example, the EC50
values for CVN against the HIV-1 R5 strains HIV-1(Ba-L), HIV-
1(Ada-M) and HIV-1(89.6) are 17 nM, 1.7 nM and 36.8 nM,
respectively [28,29]. Our data demonstrated that LCVN and
10 K PEG-ALD-LCVN retained the specificity and potency of the
anti-HIV-1 activity of CVN and suggested the therapeutic
potential of these CVN derivatives against R5 and other HIV-1
strains.
Conclusions
A linker-extended CVN derivative, LCVN, and its PEGylated
product, 10 K PEG-ALD-LCVN, were rationally designed and
constructed after molecular docking and experimental approaches.
Twelve residues were determined to be involved in the targeting of
the reverse parallel CVN dimer to oligosaccharide ligands, among
which Leu-1 (the N-terminal leucine in the B chain of the CVN
dimer) was the most important hot spot residue. Eight residues
were suggested to interact with the oligosaccharides in the parallel
CVN dimer, with Glu-41 being one of the most important hot spot
residues. Both LCVN and 10 K PEG-ALD-LCVN retained the
oligosaccharide specificity of CVN binding to high mannose N-
glycans with .1 terminal Mana122Man moieties in gp120 and
gp41. It was exciting that the CVN derivatives exhibited potent
anti-HIV activity with remarkably decreased cytotoxicity. The
improved biological compatibility of these 2 CVN derivatives
suggested that these modifications could produce promising
microbicide candidates and provide a template for a universal
strategy for the PEGylation of biologic candidates without
introducing point mutations. The CVN-oligosaccharide interac-
tion analysis provided a possible explanation for the loss of anti-
HIV-1 activity with N-terminal PEGylated CVN and suggested
the dominant conformation of the CVN dimer in solution.
Materials and Methods
Chemicals, Reagents and Media
All the chemicals and reagents were obtained from Sigma (St.
Louis, MO, USA) unless otherwise stated. All the media and
supplements, including fetal bovine serum (FBS), were purchased
from Invitrogen (New York, NY, USA) unless otherwise stated.
Recombinant LCVN and the PEGylated product 10 K PEG-
ALD-LCVN (Figure 5) were prepared in-house by a process
modified from Gao et al [11].
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Cell Culture
The immortal human HaCaT keratinocyte cell line, purchased
from the China Center for Type Culture Collection (Wuhan
University, Wuhan, China), was propagated in Eagle’s minimal
essential medium (MEM) supplemented with 10% FBS, 1.0 mM
sodium pyruvate, 0.1 mM non-essential amino acids and 1.5 g/L
sodium bicarbonate. The MT-4 T lymphocyte cell line (NIH
AIDS Reagent Program, Germantown, MD, USA) was cultured
in RPMI 1640 medium containing 10% FBS and 0.22% sodium
bicarbonate. The cells were cultured at 37uC in a humidified
atmosphere with 5% CO2.
Enzyme-linked Immunosorbent Assay (ELISA)
The target binding activity of LCVN to HIV-1 gp120 and gp41
was determined using an ELISA-like assay as described previously
[30]. Briefly, 100 ng of gp120 or gp41 derived from HIV-1HXBc2
(BPB, Beijing, China) was coated onto a 96-well plate, which was
subsequently incubated with serially diluted LCVN or 10 K PEG-
ALD-LCVN. The bound proteins were detected using a rabbit-
anti-CVN polyclonal antibody (1:10000, in-house preparation)
and goat-anti-rabbit IgG-HRP (1:3000) followed by chromogenic
development with 3, 39, 5, 59-tetramethylbenzidine (TMB) at l450.
Molecular Docking
CVN exists predominantly as a monomer in solution and as a
domain-swapped dimer in crystals, producing both parallel (head-
to-head fashion) and reverse-parallel dimer conformations. The
crystal structures of parallel CVN (2PYS) and reverse-parallel
CVN (3GXY) (Figure S1) were downloaded from the RCSB
Protein Data Bank (http://www.rcsb.org/pdb) [31]. To determine
the optimum scoring function, docking experiments were
performed for all the protein-ligand complexes using 3 molecular
docking platforms (Flex_X [32], CDOCKER (DS 2.1, Accelrys)
[33] and MOE [32]). The active sites were identified using the
crystallographic ligand for all the datasets. All the docking
experiments reported here were performed with the default
parameters. Based on the ligand-protein binding energy, the 30
top-ranked docking poses were retained for further study.
The optimum docking program for CVN was selected using the
root-mean-square deviation (RMSD) and the scores of the re-
docking of the ligands to the known CVN crystal structures. After
re-docking the ligands to 2PYS and 3GXY, the RMSD values with
Flex_X ranged from 0.1 to 9.2, and the re-docking scores with
CDOCKER were .0 kcal/mol. For MOE, the RMSD values
were ,1, and the docking scores were ,235.6 kcal/mol,
indicating that MOE was the most appropriate program for
CVN docking.
MOE has 2 docking placement methods, Alpha Triangle
matcher and Proxy Triangle [34]. The active site was minimized
using the AMBER 99 force field in MOE with the default
parameters. All the oligosaccharides were docked, employing
Triangle Matcher as the placement method and London dG as the
first scoring function. The refinement was set to force field
(AMBER 99), and the docked poses were energy-minimized in the
receptor pocket. Affinity scoring was utilized to assess and rank the
receptor-ligand complexes. A low docking score correlated with
increased binding affinity.
To screen novel and bioactive targets of CVN, the 2D structures
of 53 oligosaccharides were converted into 3D structures. With the
energies minimized, the moieties were docked into the binding
sites of 2PYS and 3GXY by MOE. A consensus score (CSi) was
calculated from the normalized docking score of 3GXY (Xi) and












Function Xi is the normalized docking score of an oligosaccha-
ride to 3GXY, and xi is the (un-normalized) docking score of an
oligosaccharide to 3GXY. Function Yi is the normalized docking
score of an oligosaccharide to 2PYS, and yi is the (un-normalized)
docking score of an oligosaccharide to 2PYS. Min(2x) and
Min(2y) are the minimum scores among the values determined for
the 53 oligosaccharides. Max(2x) and Max(2y) are the maximum
scores among the values determined for the 53 oligosaccharides.
Centrifugal Ultrafiltration-HPLC
A centrifugal ultrafiltration-HPLC assay was utilized to
determine the oligosaccharide binding properties of the LCVNs
as described by Katoh et al. [35]. Briefly, the LCVNs were
incubated with pyridylaminated (PA)-oligosaccharides (Takara Bio
Inc., Otsu, Shiga, Japan) in 50 mM Tris-HCl (pH 7.0) at room
temperature for 60 min. The reaction mixture was centrifuged
(14,000 xg for 15 min) in a centrifugal ultrafiltration tube
(Sartorius Stedim, Boston, MA, USA) with a molecular weight
cut-off value of 5,000 Daltons. The unbound PA-oligosaccharides
(Ounbound) and the total amount of added PA-oligosaccharides
(Oadded) were quantified from the peak area detected on a TSKgel
ODS 80TM column (4.66150 mm) (Tosoh Corporation, Tokyo,
Japan) at l320/400 for the coupled fluorescence group. The bound
PA oligosaccharide (Obound) was defined as the volume of Oadded
minus that of Ounbound. The binding activity was expressed as the
ratio of Obound to Oadded and presented as % binding.
MTT Assay
The in vitro cytotoxicity of the LCVNs was determined via a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay in HaCaT cells. LCVNs were serially diluted from
12 mM to 0.375 mM, added to a monolayer of HaCaT cells in 96-
well plates and incubated for either 24 or 48 h. The MTT solution
was added for color development. The absorbance was measured
at l570/630, and the data were plotted to obtain the 50% cell
inhibitory concentration (CC50).
WST-1 Assay
The in vitro anti-HIV-1 activity of the LCVNs was determined
using the water-soluble tetrazolium salt 2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4- disulfophenyl)-2H-tetrazolium (WST-1) in a
P3 laboratory. For this assay, 2-fold dilutions of LCVNs were
mixed with HIV-1/IIIB (100 TCID50/50 mL), added to MT-4
cells (104 cells/100 mL/well) in 96-well microplates and incubated
for 96 h. WST-1 was added to quantitate the number of viable
cells at l450/650. The cytotoxicities of the LCVNs in MT-4 cells
were simultaneously determined in virus-free wells. Azidothymi-
dine (AZT) was utilized as a positive control. The 50% inhibitory
concentration (IC50), 50% cytotoxicity concentration (CC50) and
selectivity index (SI, the ratio of CC50 to IC50) were determined.
Cell-to-cell Fusion Assay
Cell-to-cell fusion assays and cell-to-cell virus transmission
assays, also known as syncytium formation assays, were performed
with a co-culture system comprised of MOLT-4 (ATCCH CRL-
1582TM, Manassas, VA, USA) and MOLT-4/IIIB cells as
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previously described [36]. MOLT-4/IIIB cells are chronically
HIV-1-infected MOLT-4 cells that allow HIV-1 replication and
induce syncytium formation between uninfected MOLT-4 cells.
MOLT-4 cells (2.56105/250 mL) and MOLT-4/IIIB cells
(2.56105/250 mL) were mixed and seeded in 24-well plates
(Falcon). LCVN and PEGylated LCVN were diluted 4-fold with
RPMI-1640 containing 10% fetal calf serum and antibiotics.
Individually cultured MOLT-4 and MOLT-4/IIIB cells and co-
cultures of MOLT-4 and MOLT-4/IIIB cells without LCVN or
PEGylated LCVN were utilized as controls, and co-cultured cells
treated with LCVN or PEGylated LCVN at three different
concentrations (452, 113 and 28 nM) were examined as the test
conditions. Cytopathic effects indicated by the presence of syncytia
formation were observed and recorded using a microscope after
24 h at 37uC with 5% CO2. The number of viable cells was
determined by trypan blue dye exclusion, and the fusion index (FI)
was calculated as the following: FI = 12[cell number in a test well
(MOLT-4+MOLT-4/IIIB)]/[cell number in control well
(MOLT-4 only)]. The fusion inhibition rate (FIR)
(%) = [12(FIT/FIC)]6100 was also calculated, where FIT was
the fusion index of the test sample and FIC was that of the co-
cultured control [12].
Supporting Information
Figure S1 The three-dimensional (3D) structures of CVN
utilized in this study. 2PYS, 1IIY and 2RDK are parallel
domain-swapped dimers of CVN, and 3GXY and 3GXZ are
reverse-parallel domain-swapped dimers of CVN. The structure
coordinates of the protein-ligand complexes were retrieved from
the Protein Data Bank (PDB) for the comparative molecular
docking studies.
(TIF)
Table S1 Hot spot residues in CVN that target different ligands
as determined by structural resolution approaches.
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